Physician profile
Rami A Mortada
NPI 1174720205
$105,365.84
in general payments reported to CMS, 2019-2025
55 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $21K · 2021: $15K · 2022: $17K · 2023: $3,898 · 2024: $2,578 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,809 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,276 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,808.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,276.00 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91,548.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $2,467.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $1,082.62 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $1,032.99 | 2019-2025 | Evenity, Tepezza, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,021.35 | 2019-2025 | Farxiga |
| Abbott Laboratories | $873.33 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $795.19 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $727.89 | 2020-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.31 | 2019-2025 | Jardiance |
| Abbvie INC. | $610.28 | 2019-2025 | |
| Insulet Corporation | $568.20 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $417.76 | 2019-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $410.44 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $339.01 | 2021-2025 | Recorlev, Gvoke Hypopen, Keveyis |
| Amneal Pharmaceuticals LLC | $338.24 | 2019-2025 | Unithroid |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $270.18 | 2019-2021 | |
| Pfizer INC. | $226.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $191.90 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $108.93 | 2021-2025 | Contrave, Nexletol |
| Radius Health, INC. | $107.50 | 2023-2025 | Tymlos |
| Amryt Pharma Holdings LTD | $91.03 | 2020-2023 | Myalept |
| Ibsa Pharma INC. | $82.80 | 2019-2020 | |
| Eusa Pharma (US) LLC | $81.66 | 2022 | |
| Medtronic Minimed, INC. | $80.41 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $78.66 | 2019-2020 | |
| Sandoz INC. | $75.62 | 2019-2020 | |
| Nevro Corp. | $71.33 | 2021-2023 | Senza |
| Almatica Pharma LLC | $68.02 | 2024-2025 | Teriparatide, Loreev Xr |
| Medtronic, INC. | $64.98 | 2021-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $64.30 | 2019-2020 | |
| Beta Bionics, INC. | $63.49 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $58.45 | 2025 | Twiist |
| Vivus LLC | $55.61 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $55.44 | 2020-2022 | |
| Globus Medical, INC. | $49.86 | 2025 | Senza |
| Chiasma, INC. | $46.99 | 2021 | |
| Neurocrine Biosciences, INC. | $46.84 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $44.31 | 2021 | |
| Tandem Diabetes Care, INC. | $38.82 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $38.00 | 2023 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $36.87 | 2021 | |
| Antares Pharma, INC. | $31.63 | 2021-2024 | Xyosted |
| Astellas Pharma US INC | $26.92 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $23.90 | 2023 | |
| Shire North American Group INC | $23.05 | 2019 | |
| Chiesi USA, INC. | $21.72 | 2025 | Myalept |
| Recor Medical INC | $21.57 | 2025 | Paradise Ultrasound Renal Denervation System |
| Horizon Therapeutics Plc | $19.62 | 2023 | Tepezza |
| Halozyme INC | $18.15 | 2023 | |
| Aegerion Pharmaceuticals, INC. | $17.13 | 2019 | |
| Kyowa Kirin, INC. | $16.64 | 2023 | |
| Embecta Corp. | $15.07 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Becton, Dickinson and Company | $14.62 | 2021 | |
| Senseonics, Incorporated | $13.00 | 2019 | |
| Alvogen INC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Mortada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.